Clouds Will Pass
by PC Elliott

Acrylic on Board, Inspired by Sue, living with SM

A first-of-its-kind art and storytelling program by Blueprint Medicines and Twist Out Cancer, illuminating the diverse experiences of people living with SM through bold expressions of identity, hope, and resilience.

COLORS of SM
Expressions of Life with Systemic Mastocytosis

blueprint™ MEDICINES

2024

Sustainability Highlights

Turning innovation into impact

Nasdaq: BPMC

Contents

About This Report

This report highlights recent progress related to our sustainability strategy and initiatives and serves as an update to our more comprehensive 2023 Sustainability Report. Please refer to our 2023 report for a holistic picture of our established sustainability strategy and ongoing efforts at Blueprint Medicines.

Unless otherwise noted, all quantitative environmental, social and governance (ESG) data provided in this report covers our fiscal year 2024 (FY 2024), reflecting data for the period from January 1 through December 31, 2024.

1

Introduction

A Message from Our CEO

At Blueprint Medicines, we are driving growth and innovation through operational excellence. We strive to fundamentally shift the way allergic inflammatory diseases are treated by targeting the mast cell.

We had a tremendous year in 2024, with the ongoing successful launch of AYVAKIT®/AYVAKYT® (avapritinib), delivering $479 million in revenue globally. Our success is grounded in our demonstrated commitment to patients and our employees as we build a sustainable business to drive long-term value for shareholders. We do this by operating with the highest ethical standards and by strategic management of sustainability metrics with material impact on our business. Throughout this update, we share our vision and progress across sustainability factors for which we can continue to make an impact. I am incredibly proud of how all of our Blueprint team members show up every day to support each other as we work toward our shared mission to improve the lives of patients.

Warm regards,

Kate Haviland
President, Chief Executive Officer and Director

About Blueprint and Our Approach to Sustainability

Blueprint Medicines is a global biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology.

Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with AYVAKIT, which we are bringing to patients with systemic mastocytosis (SM) around the world. Leveraging our integrated research, development, and commercial capability and infrastructure, we aspire to scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials.

MORE INFORMATION

- About Blueprint Medicines
- Our Mission and Values



Kristine G., living with SM

We seek to deliver long-term value to patients and shareholders while responsibly managing our business to enable a sustainable future for all of our stakeholders. In 2024, we conducted a materiality assessment to better understand critical factors linked to both business success and sustainability, through which we defined the following strategic pillars.

Commitment to patients	Employees and culture	Responsible business practices
We work with urgency to deliver safe and effective therapies aimed at improving and extending patients' lives.	We are intentional in fostering a culture of transparency, inclusivity and equity. We prioritize employee development, engagement, growth and recognition while investing in the health and well-being of our teams.	We lead with integrity, prioritize operational efficiency and uphold a strong governance framework to create long-term value and trust with stakeholders.

Oversight

We apply rigorous governance around our sustainability strategy to ensure business continuity. The Nominating and Corporate Governance Committee of our board of directors oversees ESG strategy. At the management level, our ESG Steering Committee, composed of a subset of the executive team, guides sustainability strategy. It works closely with the ESG Working Group, composed of technical experts across the business, which manages day-to-day operations. For more information, see our 2023 report.

2

Commitment to Patients

UN SDG ALIGNMENT

At its core, our mission at Blueprint is to deliver life-changing medicines to patients with serious medical needs. To help do this, we strive for equitable access to our medicines and engage in patient education and support. We are focused on raising awareness of SM through our broad education efforts, including peer-to-peer initiatives for both healthcare providers and patients, and leading efforts to make testing more accessible to facilitate an accurate diagnosis.

2024 Highlights

- Provided approximately $44.5 million worth of AYVAKIT for free to U.S. patients and $4.4 million in co-pay assistance in 2024.
- Market research demonstrated that 95% of AYVAKIT patients strongly agree they are satisfied with their therapy.
- Drove 80+ SM publications, 380+ regional congresses, 260+ healthcare provider (HCP) speaker programs, 36 HCP product theaters that reached and educated approximately 2,000 HCPs, and 19 patient programs to increase understanding of SM and AYVAKIT.
- Sponsored a patient and caregiver conference organized by The Mast Cell Disease Society (TMS).

MORE INFORMATION

- Early Access Policy
- Patient and Family Support
- YourBlueprint Overview

Patient Access and Affordability

Providing more patients with affordable treatment has been a cornerstone of Blueprint from the beginning. Efforts include initiating global Early Access Programs for our investigational therapies and designing a robust U.S. patient support program to assist patients in accessing our commercially available medicines.

Pricing Principles: Our pricing approach reflects our treatments' significant benefits in rare patient populations, our commitment to equitable patient access, and the development of innovative science and sustainable research. We are committed to reinvesting product revenues into research to bring even more treatment advances to patients, including investing $341.4 million in research and development in 2024—nearly 50% of our 2024 operating expenses.

Early Access Programs for Investigational Therapies: We acknowledge the urgency felt by patients and their families facing a serious or immediately life-threatening disease when there are no standard treatment options available or when all treatment options have been exhausted. We are committed to providing early access programs for our investigational medicines for patients most in need while maintaining our focus on moving our investigational medicines through clinical trials and ultimately toward regulatory approvals. Blueprint's Early Access Programs are overseen by the Early Access Strategy and Governance Steering Committee, which consists of senior leaders across the business.

Patient Assistance: YourBlueprint® is our comprehensive U.S. patient support program that helps patients start and stay on therapy while minimizing out-of-pocket costs. Resources include co-pay assistance, a patient assistance program, dedicated case manager support and temporary treatment to help address delays in insurance coverage.

Patient Education and Support

At Blueprint, we partner with the patient community to strengthen awareness, education and access. In 2024, we launched a one-on-one patient mentor program, supported patient and family events with SM experts, and sponsored the TMS MastCellCon, a patient and caregiver conference focused on mast cell diseases.

Our patient affairs and market access teams also helped patients navigate the complexities of Medicare, including important changes to the Part D prescription drug benefit made by the Inflation Reduction Act of 2022. In partnership with policy experts and the American Cancer Society Cancer Action Network (ACS CAN), Blueprint sponsored a webinar to better prepare patients for the upcoming changes. In addition, we proactively contacted all YourBlueprint-enrolled Medicare Part D patients to help them navigate the new benefit redesign options.

Colors of SM

In 2024, Blueprint partnered with the patient organization Twist Out Cancer to introduce Colors of SM: Expressions of Life with Systemic Mastocytosis, a novel art program highlighting patients' stories and experiences. The program matches volunteer artists with people living with SM to create unique pieces of artwork that reflect their personal journeys with the disease. Learn more here.

Sue, living with SM, and **PC Elliott**, artist

Health Equity and Advocacy

Blueprint is committed to building equity into our clinical and commercial practices by increasing scientific understanding of our target disease states and striving to alleviate social determinants of health to enable diverse clinical trial participation and expanded access to our treatments for all patients.

2024 initiatives:

- Collaborated with health systems to better understand and publish on health disparities in SM, focusing on the increased disease burden, prolonged diagnosis times and lower disease understanding among non-white populations.
- Partnered with BlackDoctor.org to provide thought leadership on health equity and participated on a panel at the Community Voices in Health Equity Summit.
- Revised the company's standard clinical trial site selection feasibility questionnaire to include a diversity module to better understand capabilities in enrolling underserved communities.
- Drafted a clinical trial diversity checklist in alignment with FDA Guidance to be implemented in all 2025 Blueprint clinical trials.

3

Attracting, Engaging and Retaining Our Talent

UN SDG ALIGNMENT

At Blueprint, a core component of our organizational culture and operating model is the integration of diverse skillsets, expertise, life experiences and educational backgrounds to help us solve complex scientific, medical and business challenges inherent in bringing innovation to patients.

Reflecting our approach to diversity, we recruit and hire highly qualified talent with a breadth of perspectives, and we work hard to ensure our employees have the support they need to individually excel and achieve operational excellence together. To sustain this culture, we are committed to cultivating an employee experience that empowers high performance, fosters well-being and instills a deep sense of belonging. By intentionally building and nurturing this environment, we drive operational excellence, spark continuous innovation and create a workplace where our teams can truly thrive.

2024 Highlights

- Recognized as a Top Place to Work by the Boston Globe for the third consecutive year, and one of 26 companies recognized as a DEI Champion.
- Recognized as a Top Workplace USA by USA Today for the third consecutive year as well as a top employer in Switzerland by Top Employers Institute. Review the full list of awards for 2024 here.
- Launched the employee-led Culture Team to offer events and activities throughout the year to help our teams around the world stay connected.
- Designed and executed a new workshop for managers of students in our early-career programs to enhance leadership mindset, people management strategies and behavior, grounded in Blueprint's core values.
- Supported early-career programs for 60 students across our U.S. and European offices to strengthen our future talent pipeline.

MORE INFORMATION

- Early Career Programs
- Employee Benefits

Learning and Development

At Blueprint, growth isn't optional—it's essential. Learning isn't just about formal training; it's about real-world experiences, exposure to new challenges, and the opportunity to push boundaries and innovate boldly.

We believe continuous learning fuels both individual and business success. That's why we invest in mentorship, team effectiveness, skill-building and development planning—ensuring employees have the tools to reach their full potential. Guided by five core competencies, we create regular touchpoints to assess growth, foster career advancement and drive impact. In 2024, employees engaged in an average of 64 hours of formal learning and development, reinforcing our commitment to experiential learning that empowers people to thrive.

Community Impact

We believe Blueprint has a responsibility to contribute to and improve the communities where we live and work. In 2024, we hosted field trips to our office in collaboration with organizations such as Big Brothers Big Sisters, LEAH Project and Harvard Black Postdoc Association to provide exposure to the biopharmaceutical industry. For the third year in a row, we also partnered with the Prison Book Program and Catie's Closet to hold a book drive and clothing drive, respectively.

2024 Community Giving Metrics

Company charitable contributions	$476,000
Total number of organizations supported	39
Employee donations matched through our corporate match programs	~$17,000
Employee volunteer hours	~1,000

Engagement and Feedback

Our annual Engagement and Enablement Survey is a cornerstone of our commitment to open dialogue, ensuring every voice shapes our evolving employee experience.

Results from the 2024 survey, completed in early 2025 with 96% employee participation, showed 95% of employees are proud to work at Blueprint. In addition, engagement scores were high, exceeding the top 10% of benchmarked companies, and generally consistent regardless of gender, race/ethnicity, geography and other demographics.

Beyond surveys, we engage in continuous two-way feedback, including semi-annual 360-degree assessments from peers, leaders and direct reports to drive accountability, growth and alignment with our values. To ensure fairness and transparency, we take steps to mitigate any forms of bias in our performance review and promotion processes through our Bias Interrupter Program. Our impartial bias interrupters challenge perspectives in an effort to ensure employees are assessed on consistently applied performance criteria, reinforcing our merit-based approach. As a result, our employee turnover remains well below industry averages—proof that an open, responsive culture leads to lasting engagement and retention.

Equity, Diversity and Inclusion (ED&I)

At Blueprint, we define ED&I as fostering an environment of fair treatment and full participation for all to benefit. Across our workforce, we seek to integrate diverse skillsets, expertise, life experiences and educational backgrounds to navigate complex challenges and achieve our business goals. Furthermore, we are dedicated to empowering our employees and external stakeholders through equitable and inclusive practices. We lead with an integrated approach that ensures accountability and sustainability across our business and delivers on our mission to improve the lives of patients.

- **People:** We cultivate dynamic teams with diverse expertise, experience and backgrounds, harnessing innovation to tackle complex medical challenges. Through strategic talent acquisition, comprehensive development programs and access to real-world experiences, we empower every employee to grow, thrive and drive meaningful impact.
- **Patients:** We recognize disease does not discriminate. We address social determinants of health to drive health equity. We engage the patient community throughout the drug development process and strive to ensure our treatments are safe, effective and accessible to all who can benefit from them.

*Employee Demographic Metrics**

Global Company Snapshot 2024	
Non-U.S. employees	78
U.S. employees	561

Global Gender Diversity (%)	
Female	58%
Male	42%

Racial Diversity of U.S. Workforce (%)	
Native American or Alaska Native or Pacific Islander	0.4%
Asian	25%
Black or African American	6%
Hispanic or Latinx	5%
Two or more races	0.4%
White	64%

Educational Background	
Doctorate or master's degree	33%

Executive Team	
Members	12
Female members	6
Members from underrepresented populations	4

Board of Directors	
Members	10
Female members	3
Members from under-represented populations	2

Our Core Values

**Data is reported as of December 31, 2024. Underrepresented populations are defined as those who self-reported as Black or African American, Hispanic or Latinx, Native American, Alaska Native or Pacific Islander, or LGBTQ+ or who identified as two or more races.*

4

Environment

UN SDG ALIGNMENT

We believe human health is inextricably linked to our environment, and responsible environmental stewardship is an important part of our company's mission to help patients live better lives.

2024 Highlights

- Completed our first Scope 1 and 2 greenhouse gas (GHG) inventory.
- Established formal safety committees and completed two key audits on our environmental, health and safety (EHS) program.

MORE INFORMATION

- Environmental Statement

Measuring our Emissions

In 2024, we calculated our Scope 1 and 2 GHG emissions in alignment with the GHG Protocol to better understand our impact. We leveraged primary data to calculate most of our emissions and supplemented with estimates where needed. Possible process emissions associated with our labs were excluded from this initial inventory.

	mtCO2e
Scope 1 Emissions	
Scope 1	208.18
Scope 2 Emissions	
Scope 2 (Market Based)	819.84
Scope 2 (Location Based)	815.04
Total Calculated Emissions	
Total Scope 1 & 2 (Market Based)	1,028.02
Total Scope 1 & 2 (Location Based)	1,023.22

Environmental Health and Safety Program

Our EHS program, aligned with federal and local regulations, ensures the health, well-being and safety of our employees. In 2024, we implemented several key improvements to our health and safety management system to enhance safety governance, compliance and continuous improvement. This includes establishing formal safety committees, initiating a structured audit strategy with the completion of two key audits of our EHS programs, revising safety procedures for handling potent compounds, and delivering in-person emergency response training to lab employees. All employees continue to receive new-hire safety training.

Health and Safety Metrics for FY2024

Total OSHA recordable incident rate (Cambridge locations)	0.36
Employee safety training hours	347

Minimizing the Environmental Impact of Products

Our commitment to safety and environmental stewardship includes ensuring that any hazardous materials are managed appropriately throughout their lifecycle. During the R&D phase, active pharmaceutical ingredients are evaluated through environmental risk assessments, facilitating proper storage, handling and disposal to minimize environmental impact and prevent contamination.

Water and Waste Management

We use a reverse osmosis water filtration system to provide purified water to our Cambridge headquarters, with reject water diverted. We also pretreat laboratory wastewater daily before it is discharged. Scientists receive new-hire and annual trainings on wastewater management procedures, including our Chemical Hygiene Plan.

Lab waste is segregated according to the primary type of hazard (chemical, biological or radioactive), and the appropriate labeling, storage and disposal procedures are followed. Routine internal inspections and external environmental audits are conducted to ensure compliance.

Partnership With GreenLabs

Blueprint partners with a local, Boston-based recycling company called GreenLabs that specializes in collecting and recycling plastic items from the lab science industry that are not accepted at large, municipal recycling sorting facilities. These include pipette tip boxes, wafers, lids, media bottles and conical tub racks, which would otherwise go to a landfill.

In 2024, we recycled 1,335 pounds of plastic from our Cambridge lab facility. Since our partnership started in 2022, Blueprint has recycled 4,134 pounds of plastic with GreenLabs.

5

Responsible Business Practices

UN SDG ALIGNMENT

Under the leadership of our board and executive team, we are committed to good governance as an essential business practice and component of our sustainability efforts. We apply high ethical, compliance and legal standards across our operations.

2024 Highlights

- Completed an annual Enterprise Risk Assessment, incorporating business, technology, geopolitical and other risk domains, and reviewed results with the executive team and board.
- Held over 30 artificial intelligence (AI) training sessions to raise awareness on risks and responsible use of AI.
- Engagement & Enablement Survey results show 92% of employees believe Blueprint operates with strong ethical standards.

MORE INFORMATION

- Compliance and Ethics Program
- Code of Business Conduct and Ethics
- Privacy Policy

Corporate Governance and Risk Management

At Blueprint, we maintain a strong governance framework aligned with our industry peers as well as federal, state and local legal and regulatory requirements, with routine evaluations to ensure compliance and best practice. Our board is composed of highly qualified, experienced and diverse directors focused on driving Blueprint's long-term success. To help support priorities for board and management focus, we conduct an annual Enterprise Risk Assessment that covers risk areas across the organization, including the impact of evolving global dynamics on our supply and trade chains and of climate-related risks.

Additional details on director expertise and risk management can be found in our proxy statement and annual report, available on our Investor Relations website.

Business Ethics and Integrity

Our comprehensive global Compliance Program and Code of Business Conduct and Ethics (Code) set the standards for how we conduct business. In 2024, we prioritized continuous improvement and assessment of our programs, including refreshing our U.S. Field Manual as well as our training on the Code. Our training completion rate was 99% across the business.

Features of Blueprint's Global Compliance Program:

- Oversight from the Chief Compliance Officer, with annual reporting to the board
- Training on compliance policies for all employees as well as certain contractors
- BlueCares hotline for employees to raise concerns at any time

Read more in our 2023 Sustainability Report.

Government Relations and Public Policy

Blueprint primarily engages in public policy through industry trade association memberships, including through the Biotechnology Innovation Organization. We do not maintain a political action committee and did not make any contributions to political parties or candidates in 2024.

Quality Program

Our Global Quality Management System, which includes the Global Quality Manual, ensures high product quality and data integrity. We maintain regular quality management reviews, a quality training program, an audit program, an incident management process and a Material Review Board who assesses any nonconforming products. For more detailed information on our approach to and process around maintain quality in our operations, please refer to our 2023 Sustainability Report.

Data Security and Privacy

Blueprint concentrates on securing, testing and optimizing our technology ecosystem to protect the integrity of our data and the data of patients and our personnel. Our Information Security Policy, security controls and operating procedures are informed by the National Institute of Standards and Technology (NIST) cybersecurity framework, and a cross-functional Data Privacy Taskforce oversees day-to-day compliance with global data protection and privacy regulations. We proactively initiate monthly cybersecurity assessments and network vulnerability scans in addition to monitoring threats in real time. All employees receive annual information security and privacy training, with 96% completion in 2024.

6

Frameworks and Standards

UN SDG ALIGNMENT*

** For more information, please refer to our 2023 Sustainability Report.*

Sustainability Accounting Standards Board (SASB)

SASB STANDARDS
Now part of IFRS Foundation

We align our disclosures with the Sustainability Accounting Standards Board (SASB)—now housed under the International Sustainability Standards Board (ISSB)—related to the biotechnology and pharmaceuticals industry. The standards help ensure that we address the ESG factors most relevant to our business.

Topic	Accounting Metric	SASB Code	Response
Safety of Clinical Trial Participants	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	HC-BP-210a.1	We maintain robust regulatory review and approval procedures in our clinical development programs. Qualified clinical research organizations conduct our clinical trials, overseen by experienced study managers trained in our procedures. We protect patient safety through informed consent, routine safety monitoring and reporting. This includes independent Data and Safety Monitoring boards and internal quarterly safety review meetings, following Good Clinical Practice guidelines and country-specific standards. We maintain standard operating procedures (SOPs) on recovery of distributed investigational medicinal products in the case of complaints, adverse event reports, product quality issues and mandatory regulatory decisions.
	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	HC-BP-210a.2	No trials were inspected that resulted in classification of VAI/OAI.
	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	HC-BP-210a.3	No material losses resulting from such legal proceedings.
Access to Medicines	Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index	HC-BP-240a.1	Refer to the Commitment to Patients section.
	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	HC-BP-240a.2	We do not have any products that qualify for the WHO List of Prequalified Medicinal Products.
Affordability & Pricing	Percentage change in (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	HC-BP-240b.2	We believe the price of our medicines reflects their significant benefits. We're committed to enabling patient access, and we've designed a robust patient support program in the U.S. to help patients start and stay on therapy while minimizing out-of-pocket costs. In addition, we're committed to reinvesting product revenues into research to bring even more treatment advances to patients with mast cell-mediated diseases and cancer. We periodically consider price increases consistent with inflation.
	Percentage change in (1) list price and (2) net price of product with largest increase compared to previous year	HC-BP-240b.3	

Topic	Accounting Metric	SASB Code	Response
Drug Safety	Products listed in public medical product safety or adverse event alert databases	HC-BP-250a.1	In the instance of any adverse events, quality events or product complaints, the Blueprint Quality Event Process is used to investigate impact and implement immediate corrective actions, as well as approving additional corrective and preventive actions for remediation. No Blueprint products are currently listed in the MedWatch Safety Alerts database. The FDA's MedWatch Safety Alerts for Human Medical Products database can be publicly accessed here.
	Number of fatalities associated with products	HC-BP-250a.2	This information for our products can be found in the FDA's Adverse Event Reporting System here.
	Number of recalls issued, total units recalled	HC-BP-250a.3	We maintain robust SOPs that follow GxP and applicable regulations in the event of a commercial product recall. Our Executive Recall Committee and recall execution team assess the potential risk to patients, evaluate situations that may affect safety or quality, and develop a recall strategy. In 2024, we had no product recalls.
	Total amount of product accepted for takeback, reuse, or disposal	HC-BP-250a.4	Amount of product is negligible.
	Number of enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	HC-BP-250a.5	We have not had any cGMP violations or enforcement actions.
Counterfeit Drugs	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	HC-BP-260a.1	We are committed to complying with the Drug Supply Chain Security Act (DSCSA) to safeguard our supply chain against suspect, illegitimate and counterfeit products. Our SOPs include requirements on product tracing, product identifiers, authorized trading partners and verification. We have implemented fully compliant serialization practices in our supply chain for commercial products such that every unit has a unique identifier, enabling the relevant parts of the product supply chain to be halted if a transaction takes place involving a falsified product.
	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	HC-BP-260a.2	We have internal processes in place to ensure risks associated with unsafe products are managed. In 2024, no alerts have been received.
	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	HC-BP-260a.3	None.

Topic	Accounting Metric	SASB Code	Response
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	HC-BP-270a.1	No material losses resulting from such legal proceedings.
	Description of code of ethics governing promotion of off-label use of products	HC-BP-270a.2	We help healthcare professionals and patients make informed decisions by honestly educating them about our products. Blueprint promotional materials must meet the requirements of applicable regulations and industry codes. Our Promotional and Non-Promotional Medical Interactions policies guide our responses to questions on products prior to approval, and field employees who engage in promotional interactions with customers receive training on applicable regulations. The U.S. Field Manual is another Blueprint tool that provides comprehensive guidance on compliance policies to support our U.S. field personnel. The manual covers key laws and principles, conflicts of interest, promotional interactions, non-promotional and medical interactions, interactions with patients and patient advocacy groups, and adverse event and product complaint reporting.
Employee Recruitment, Development and Retention	Discussion of talent recruitment and retention efforts for scientists and research and development staff	HC-BP-330a.1	Refer to the Attracting, Engaging and Retaining Our Employees section.
	1) Voluntary and (2) involuntary turnover rate for (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	HC-BP-330a.2	Refer to the Attracting, Engaging and Retaining Our Employees section.
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	HC-BP-430a.1	We partner with leading industry organizations, primarily in North America and Europe, to develop and manufacture our therapies following Good Manufacturing Practice regulations and guidelines. Working with outsourced Contract Development and Manufacturing Organizations, we maintain a robust program for supplier selection and qualification to ensure our partners align with our values and uphold high ethical, social and environmental standards.
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	HC-BP-510a.1	No material losses resulting from legal proceedings.
	Description of code of ethics governing interactions with healthcare professionals	HC-BP-510a.2	Refer to the Responsible Business Practices section.

Activity Metric	SASB Code	Response
Number of Patients Treated	HC-BP-000.A	We continue to prioritize access for patients through commercial and clinical trial pathways.

Activity Metric	SASB Code	Response
Number of Drugs (1) in Portfolio and (2) in Research and Development (Phases 1-3)	HC-BP-270a.2	Our portfolio includes four novel therapeutics. This includes one approved medicine, two investigational therapies in clinical development and multiple discovery programs.

Cautionary Note Regarding Forward-Looking Statements

This Sustainability Report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, without limitation; statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; the progress and benefits related to Blueprint Medicines' ESG initiatives and strategy; and our financial performance, strategy, goals and anticipated milestones, business plans, and focus. While we believe the forward-looking statements contained in this Sustainability Report are accurate, these forward-looking statements represent our beliefs only as of the date of this Sustainability Report, and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Any forward-looking statements in this Sustainability Report are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Sustainability Report, including, without limitation, risks and uncertainties related to our ability and plans in continuing to expand a commercial infrastructure and successfully launching, marketing and selling current or future approved products; our ability to successfully expand the approved indications for AYVAKIT/AYVAKYT or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of our current or future drug candidates; our advancement of multiple early-stage efforts; our ability to successfully demonstrate the safety and efficacy of our drug candidates and gain approval of our drug candidates on a timely basis, if at all; the preclinical and clinical results for our drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products or any drug candidates we are developing; our ability to develop and commercialize companion diagnostic tests for our products or any of our current and future drug candidates; our ability to successfully expand our research platform and the costs thereof; and the success of our current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

Blueprint Medicines Global Headquarters
45 Sidney Street
Cambridge, MA 02139
USA

Blueprint Medicines (Switzerland) GmbH
Baarerstrasse 8
6300 Zug
Switzerland

blueprintmedicines.com
Nasdaq: BPMC
ir@blueprintmedicines.com